[1] American Diabetes A. (8) cardiovascular disease and risk management[J].Diabetes Care, 2015,38(SupplS):49-57. [2] Bhatt DL, Eagle KA, Ohman EM, et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis[J]. JAMA, 2010,304(12):1350-1357. [3] Stam-Slob MC, van der Graaf Y, de Borst GJ, et al. Effect of type 2 diabetes on recurrent major cardiovascular events for patients with symptomatic vascular disease at different locations[J]. Diabetes Care, 2015,38(8):1528-1535. [4] Diabetes control and complications trial (dcct). Update. Dcct research group[J]. Diabetes Care, 1990,13(4):427-433. [5] UK Prospective Diabetes Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (ukpds 33)[J]. Lancet, 1998,352(9131):837-853. [6] Zoungas S, Arima H, Gerstein HC, et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes:A meta-analysis of individual participant data from randomised controlled trials[J]. Lancet Diabet Endocrinol, 2017,5(6):431-437. [7] Zoungas S, Chalmers J, Neal B, et al. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes[J]. New England J Med, 2014,371(15):1392-1406. [8] Agrawal L, Azad N, Bahn GD, et al. Long-term follow-up of intensive glycaemic control on renal outcomes in the veterans affairs diabetes trial (vadt)[J]. Diabetologia, 2018,61(2):295-299. [9] Khunti K, Kosiborod M, Ray KK. Legacy benefits of blood glucose, blood pressure and lipid control in individuals with diabetes and cardiovascular disease:Time to overcome multifactorial therapeutic inertia?[J]. Diabet Obesity Metabol, 2018. [10] Control G, Turnbull FM, Abraira C, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes[J]. Diabetologia, 2009,52(11):2288-2298. [11] Paul SK, Klein K, Maggs D, et al. The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes:A retrospective observational study[J]. Cardiovasc Diabetol, 2015,14(10). [12] Kostis WJ, Thijs L, Richart T, et al. Persistence of mortality reduction after the end of randomized therapy in clinical trials of blood pressure-lowering medications[J]. Hypertension, 2010,56(6):1060-1068. [13] Kostis WJ, Moreyra AE, Cheng JQ, et al. Continuation of mortality reduction after the end of randomized therapy in clinical trials of lipid-lowering therapy[J]. J Clin Lipidol, 2011,5(2):97-104. [14] Sever PS, Chang CL, Gupta AK, et al. The anglo-scandinavian cardiac outcomes trial:11-year mortality follow-up of the lipid-lowering arm in the UK[J]. European Heart J, 2011,32(20):2525-2532. [15] Ford I, Murray H, McCowan C, et al. Long-term safety and efficacy of lowering low-density lipoprotein cholesterol with statin therapy:20-year follow-up of west of scotland coronary prevention study[J]. Circulation, 2016,133(11):1073-1080. [16] Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes[J]. New Engl J Med, 2003,348(5):383-393. [17] Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes[J]. New Engl J Med, 2008,358(6):580-591. [18] Gaede P, Oellgaard J, Carstensen B, et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria:21 years follow-up on the steno-2 randomised trial[J]. Diabetologia, 2016,59(11):2298-2307. [19] Reddy MA, Zhang E, Natarajan R. Epigenetic mechanisms in diabetic complications and metabolic memory[J]. Diabetologia, 2015,58(3):443-455. [20] Volpe M, Cosentino F, Tocci G, et al. Antihypertensive therapy in diabetes:The legacy effect and raas blockade[J]. Current Hypertens Rep, 2011,13(4):318-324. [21] Zhang L, Chen B, Tang L. Metabolic memory:Mechanisms and implications for diabetic retinopathy[J]. Diabet Res Clin Pract, 2012,96(3):286-293. [22] 花琦琦,刘新凤,焦青,等.基于SQL Server的糖尿病信息管理与分析系统[J].中国医学物理学杂志,2016,33(11):1183-1188. |